Skip to content
The opioid epidemic has hit the United States hard in the last 25 years, killing more than 70,000 in 2019 alone, according to the […]
FDA draft guidance on non-opioid analgesics ‘inadequate’ Read More »
After unsuccessful attempts to lower Medicare Part D beneficiary cost-sharing, the Centers for Medicare & Medicaid Services (CMS) will finally wrap up a proposal
CMS will apply pharmacy price concessions at point of sale Read More »
A “march-in” petition filed under the Bayh-Dole Act, asking NIH to give competing drug companies the license to produce the prostate cancer drug Xtandi
Panel says attack on the Bayh-Dole Act threatens small businesses Read More »
A broad coalition of 77 companies and associations that are stakeholders in the aviation industry—including the Biotechnology Innovation Organization (BIO) and its member companies,
BIO, business community call for SAF tax incentives Read More »
Today on the House floor, U.S. Rep. Nanette Diaz Barragán (D-CA) spoke out against the recent Centers for Medicare and Medicaid Services (CMS) decision
Rep. Barragán: CMS Alzheimer’s drug decision is ‘a mistake’ Read More »
Does the U.S. Food and Drug Administration (FDA) question the decision by the Centers for Medicaid and Medicare Services (CMS) to limit coverage of
Does the FDA question the Aduhelm decision? Read More »
Everyone’s talking about pharmacy benefit managers (PBMs)—including the Federal Trade Commission (FTC)—but what exactly are PBMs and why do they matter in the context
What are PBMs, anyway? Read More »
A new study provides further evidence that hospitals—not manufacturers—often determine what patients and insurers pay for lifesaving cancer treatments. For patients with private insurance,
Hospitals mark up price of cancer drugs by as much as 630%, says study Read More »
House Ways and Means Committee Republicans reintroduced several tax bills that would provide critical drug R&D tax credits, particularly for small biotechs and startups.
Ways & Means Republicans reintroduce drug R&D tax credits Read More »
This month’s decision by the U.S. Centers for Medicare & Medicaid Services (CMS) to limit coverage of the Alzheimer’s drug Aduhelm to patients enrolled in
Aduhelm decision will ‘chill’ innovation, say BIO experts Read More »
